2. Academic Validation
  3. In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China

In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China

  • Diagn Microbiol Infect Dis. 2020 Nov;98(3):115129. doi: 10.1016/j.diagmicrobio.2020.115129.
Yanmei Yang 1,  Lijun Bian 2,  Xudong Hang 3,  Caiwang Yan 2,  Yan Huang 3,  Feng Ye 4,  Guoxin Zhang 5,  Guangfu Jin 6,  Hongkai Bi 7
Affiliations

Affiliations

  • 1 Department of Pathogen Biology, Jiangsu Key Laboratory of Pathogen Biology, Nanjing Medical University, Nanjing, 211166, China; Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
  • 2 Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
  • 3 Department of Pathogen Biology, Jiangsu Key Laboratory of Pathogen Biology, Nanjing Medical University, Nanjing, 211166, China.
  • 4 Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China; Helicobacter pylori Research Center, Nanjing Medical University, Nanjing, 211166, China.
  • 5 Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China; Helicobacter pylori Research Center, Nanjing Medical University, Nanjing, 211166, China. Electronic address: guoxinz@njmu.edu.cn.
  • 6 Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, 211166, China. Electronic address: guangfujin@njmu.edu.cn.
  • 7 Department of Pathogen Biology, Jiangsu Key Laboratory of Pathogen Biology, Nanjing Medical University, Nanjing, 211166, China; Helicobacter pylori Research Center, Nanjing Medical University, Nanjing, 211166, China; Department of Gastroenterology, Sir Run Run Hospital of Nanjing Medical University, Nanjing, 211166, China. Electronic address: hkbi@njmu.edu.cn.
PMID: 32739761 DOI: 10.1016/j.diagmicrobio.2020.115129
Abstract

Omadacycline and eravacycline are newly approved Tetracycline analogues with excellent activity against a broad spectrum of Gram-positive and Gram-negative microorganisms; however, no data are available regarding Helicobacter pylori. The susceptibility of 201 clinical isolates of H. pylori collected in China to omadacycline, eravacycline, and the comparator Tetracycline was determined by an agar dilution method. They showed greater activity than Tetracycline. The MIC50/90 values of omadacycline, eravacycline, and Tetracycline were 0.125/0.25 μg/mL, 0.063/0.125 μg/mL, and 0.25/1 μg/mL, respectively. Omadacycline and eravacycline were potent in vitro against all the isolates tested, including tetracycline-resistant strains, and warrant further investigation as potential Antibiotics for H. pylori treatment.

Keywords

Eravacycline; Helicobacter pylori; Omadacycline; Tetracycline.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z